SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 6896.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Golden Throat Holdings Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 48.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Golden Throat Holdings Group Company Limited’s forward annual dividend is HK$0.34 per share, paid annual. The forward yield is 17.44% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Golden Throat Holdings Group Company Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.90+HK$0.25 (+0.49%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.12% below the high.
HK$1.68+HK$0.07 (+4.35%)
JBM (Healthcare) Limited’s quoted price sits in the lower half of its reported 52-week range, 45.98% below the high.
HK$2.37-HK$0.12 (-4.63%)
Pak Fah Yeow International Limited’s quoted price sits in the lower half of its reported 52-week range, 13.19% below the high.
HK$0.36+HK$0.02 (+5.88%)
Wai Yuen Tong Medicine Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 26.53% below the high.
HK$0.33+HK$0.02 (+4.84%)
Hin Sang Group (International) Holding Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 21.69% below the high.
HK$0.03-HK$0.00 (-3.13%)
BaWang International (Group) Holding Limited’s quoted price sits in the lower half of its reported 52-week range, 35.42% below the high.
